Maximal Fat Oxidation Testing in Gilbert's Syndrome: Plasma Lipid-Mobilization Signatures from Untargeted Metabolomics
Sports medicine - open · 2026
Gilbert's syndrome didn't show a distinct metabolic signature during a FatMax test beyond the expected bilirubin difference, undercutting claims it's metabolically special.
Part of: Endurance performance and physiology: training the aerobic engine
The paper
Case-control study, n=80 (79 analyzed) age- and sex-matched adults with Gilbert's syndrome vs normobilirubinemic controls, single center (University of Vienna).
What they found
Bilirubin confirmed the groups were correctly classified (GS 33.5±13.3 vs controls 12.2±2.72 µmol/L, p<0.001), and a FatMax cycling test triggered a clear fat-mobilization signature in everyone (231 metabolites changed, including acetylcarnitines and unsaturated fatty acids). Beyond the expected bilirubin elevation, the global post-exercise metabolomic response in GS was not distinguishable from controls.
Study design
Prospective case-control study (GS vs matched controls) with an acute exercise challenge, n=80 completing the test and n=79 with usable metabolomics; this sits at the observational/mechanistic end of the hierarchy, well below an RCT or cohort study with clinical endpoints.
Methodology
Participants were age- and sex-matched and fasted 12 hours before a standardized FatMax cycle test, with blood drawn pre- and immediately post-exercise and analyzed by untargeted LC-MS metabolomics, a reasonable design for detecting broad metabolic shifts. Key threats are the single acute timepoint (no information on chronic adaptation), the large multiple-comparison burden inherent in testing hundreds of metabolites (the abstract doesn't specify the correction method, so a clinician can't verify how conservative the null result is), and the modest per-group sample size for a discovery metabolomics study, which limits power to detect anything but large between-group differences.
The appraisal
The within-subject exercise effect (bilirubin aside, a broad fat-mobilization signature in everyone) is biologically plausible and statistically robust, but the headline comparison that matters, GS vs controls, is a null finding: no evidence of a distinct metabolic signature was detected, meaning this doesn't support the popular idea that GS confers a meaningfully different fat-oxidation phenotype. A null result in a modestly powered case-control metabolomics study is informative but not definitive proof of absence of difference.
The gap
The study can't say whether a true GS-related metabolic advantage was absent, too small to detect with this sample size, or washed out by the acute single-bout design; a larger, adequately powered study with chronic training-adaptation outcomes (not just one acute test) would be needed before drawing a firm conclusion either way.
Landmark context
This builds on a body of prior work proposing that Gilbert's syndrome's mild unconjugated hyperbilirubinemia confers antioxidant or metabolic benefits (including informal claims about favorable fat oxidation in endurance athletes); this study is one of the first to test that claim directly with untargeted metabolomics and finds it unsupported beyond the bilirubin elevation itself, rather than confirming a specific landmark trial.
What to do Monday
No, this doesn't change Monday's practice: it's a mechanistic biomarker study, not a performance or clinical outcome trial, and clinicians shouldn't use GS status to predict an athlete's fat-oxidation capacity based on this evidence.
In practice
This applies to endurance athletes and coaches who have heard that Gilbert's syndrome gives a fat-burning edge, and to physios who incidentally pick up mild unconjugated hyperbilirubinemia in a training athlete's bloods. On the performance floor, keep setting fat-oxidation training zones from direct FatMax or graded exercise testing for every athlete rather than assuming GS status predicts a superior fat-oxidation phenotype; this study found no such shortcut exists. In clinic, GS still warrants the usual work-up to exclude other causes of raised bilirubin, but once confirmed, reassure the athlete that the label doesn't predict their fat-oxidation capacity or change their training prescription. Treat this as one acute, single-bout result only: it says nothing about chronic training adaptation, so use it to retire the GS-as-performance-explainer claim for now, not to close the question permanently.
The five papers that matter — every week, free.
We read the whole sports-medicine, rehab & performance literature and appraise the papers worth your time.
Get the free weekly issueRelated appraisals
Read in your language: English · Français · Deutsch · Español · Italiano · Nederlands · Dansk · Svenska